In this guest blog post, Jennifer Graff, PharmD , discusses incorporating value in coverage decisions and how this applies to AMCP's efforts in addressing value and access.
Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.
The impact of value assessment frameworks on formulary decision-making continues to create debate and influence manufacturers’ evidence-gathering strategies. Join our expert panel as they explore the evolving landscape of these frameworks, uncover payer perspectives, discuss questions and considerations regarding the real-world application, and forecast emerging trends that will shape value assessment in the future.
The impact of value assessment frameworks on formulary decision making continues to create debate and influence manufacturers’ evidence-gathering strategies. Join our expert panel as they explore the evolving landscape of these frameworks, uncover payer perspectives, discuss questions and considerations regarding the real-world application, and forecast emerging trends that will shape value assessment in the future.
Partnership Forum: This Partnership Forum identified opportunities to improve how value assessments are developed and applied to formulary decision-making and provide strategies and guidance on best practices to equip managed care pharmacists and other professionals when applying these tools to assess value and optimize patient care.
Health care services provided by pharmacists are a vital part of comprehensive patient care. AMCP supports the use of payment arrangements for pharmacists that include performance-based metrics related to these health care services, on which some of the pharmacist’s reimbursement is based.
AMCP responded in a letter to the editor of Health Affairs stressing that managed care tools work to address the misalignment between drug prices and clinical value. In her latest blog post, AMCP CEO Susan Cantrell dives deeper into the reason behind the response and how it supported the need for value-based pricing.
